{"id":"NCT06245551","sponsor":"AstraZeneca","briefTitle":"A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma","officialTitle":"A Phase III, Multicentre, Randomized, Double-blind, Single-Dose, 2-Arm, 2-Period, Crossover Study to Investigate the Efficacy of PT027 Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma (BREATH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-12-22","primaryCompletion":"2024-06-29","completion":"2024-06-29","firstPosted":"2024-02-07","resultsPosted":"2025-08-27","lastUpdate":"2025-08-27"},"enrollment":64,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma, Exercise-Induced"],"interventions":[{"type":"DRUG","name":"Budesonide/albuterol metered-dose inhaler 160/180 μg","otherNames":["PT027 (BDA MDI) 160/180 μg"]},{"type":"DRUG","name":"Placebo metered-dose inhaler","otherNames":["Placebo MDI"]}],"arms":[{"label":"A/B - Treatment with PT027 (BUDESONIDE/ALBUTEROL) 160/180 μg followed by treatment with Placebo","type":"EXPERIMENTAL"},{"label":"B/A - Treatment with Placebo followed by treatment with PT027 (BUDESONIDE/ALBUTEROL) 160/180 μg","type":"EXPERIMENTAL"}],"summary":"The purpose of this Phase III, multicentre, randomized, double-blind, single-dose, 2-period, crossover study is to assess the efficacy and safety of PT027 (budesonide/albuterol sulfate) metered-dose inhaler compared with placebo on exercise-induced bronchoconstriction in adult patients with asthma. Subjects will receive each study treatment on separate visits and undergo a treadmill exercise challenge test so that the effect of study treatment on exercise-induced bronchoconstriction can be evaluated","primaryOutcome":{"measure":"Maximum Percentage Fall From Post-dose, Pre-exercise Baseline in Forced Expiratory Volume in 1 Second (FEV₁) Observed up to 60 Minutes Post-exercise Challenge","timeFrame":"Up to 60 minutes post-exercise challenge","effectByArm":[{"arm":"BDA MDI 160/180","deltaMin":6.95,"sd":null},{"arm":"Placebo","deltaMin":24.46,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=AZ-RU-00004&amp;attachmentIdentifier=8eabc9e6-e53d-4c17-aaae-9b10b2e08ce2&amp;fileName=AZ-RU-00004_CSP_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=AZ-RU-00004&amp;attachmentIdentifier=ae80b3f5-d4df-40a3-9541-335da5e4ba22&amp;fileName=AZ-RU-00004_Statistical_Analysis_Plan_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=AZ-RU-00004&amp;attachmentIdentifier=60ac9ac9-d79d-4285-a0da-81c01107d24c&amp;fileName=AZ-RU-00004_CSR_Synopsis_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":64},"commonTop":["Diarrhoea","Headache","Bronchial irritation"]}}